Zacks Investment Research upgraded shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) from a hold rating to a buy rating in a research report released on Tuesday morning. They currently have $1.50 target price on the biopharmaceutical company’s stock.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
RGLS has been the subject of several other reports. Chardan Capital lowered Regulus Therapeutics from a buy rating to a neutral rating in a research report on Wednesday, August 2nd. BMO Capital Markets set a $1.00 target price on Regulus Therapeutics and gave the company a hold rating in a research report on Monday, June 12th. Wedbush reaffirmed an ourperform rating and set a $6.00 target price on shares of Regulus Therapeutics in a research report on Tuesday, June 13th. Finally, Needham & Company LLC reiterated a hold rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. Regulus Therapeutics currently has a consensus rating of Hold and an average target price of $3.67.
Regulus Therapeutics (NASDAQ:RGLS) traded up 0.0075% during trading on Tuesday, reaching $1.3401. 32,222 shares of the company’s stock were exchanged. The firm’s market cap is $139.08 million. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $3.38. The firm’s 50-day moving average price is $1.19 and its 200-day moving average price is $1.24.
Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. On average, equities research analysts anticipate that Regulus Therapeutics will post ($0.96) EPS for the current year.
WARNING: This report was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.themarketsdaily.com/2017/10/11/regulus-therapeutics-inc-rgls-upgraded-to-buy-by-zacks-investment-research.html.
In other news, insider Joseph P. Hagan purchased 219,780 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was bought at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the purchase, the insider now owns 241,297 shares of the company’s stock, valued at $219,580.27. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel R. Chevallard purchased 54,945 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average price of $0.91 per share, with a total value of $49,999.95. Following the purchase, the chief financial officer now directly owns 59,415 shares in the company, valued at approximately $54,067.65. The disclosure for this purchase can be found here. Insiders have bought a total of 549,450 shares of company stock valued at $500,000 in the last quarter. 4.80% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of RGLS. Quantitative Investment Management LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth $103,000. GSA Capital Partners LLP bought a new position in Regulus Therapeutics in the 2nd quarter worth about $139,000. Teachers Advisors LLC boosted its stake in Regulus Therapeutics by 15.7% in the 4th quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 9,804 shares during the period. LMR Partners LLP bought a new position in Regulus Therapeutics in the 2nd quarter worth about $164,000. Finally, Tudor Investment Corp ET AL boosted its stake in Regulus Therapeutics by 131.5% in the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 61,373 shares during the period. Institutional investors own 21.94% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.